Zometa

• Hypercalcaemia of malignancy
• Bone metastases associated with solid tumours
• Osteolytic lesions associated with multiple myeloma
• Corticosteroid-induced osteoporosis
• Increase bone mass in men with osteoporosis
• Osteoporosis in postmenopausal women
• Paget's disease of bone
• Prophylaxis of postmenopausal osteoporosis

Adult Dose (IV):

• Hypercalcemia of malignancy: 4 mg as a single dose by infusion over at least 15 minutes
• Multiple myeloma and bone metastases of solid tumors: 4 mg infusion over at least 15 minutes every 3-4 weeks

Renal Impairment: CrCl >60 mL/min: 4 mg; CrCl 50-60: 3.5 mg; CrCl 40-49: 3.3 mg; CrCl 30-39: 3 mg; CrCl <30: not recommended

Common Side Effects:

• Headache
• Nausea
• Anorexia
• Fatigue
• Osteonecrosis of jaw
• Anemia
• Bone pain
• Constipation
• Fever
• Vomiting
• Flu-like syndrome
• Hypocalcemia
• Myalgia
• Arthralgia

Use in Pregnancy: Unsafe; definite evidence of risk to the developing baby; consult your doctor.

• Patients must be appropriately hydrated prior to administration
• Serum levels of calcium, phosphate, magnesium and potassium, as well as serum creatinine should be carefully monitored
• If hypocalcemia, hypophosphatemia or hypomagnesemia occurs, short-term supplemental therapy may be necessary
• Careful renal function monitoring should be considered

Symptoms: Hypocalcemia, hypophosphatemia, and hypomagnesemia.

Treatment: Correct by intravenous administration of calcium gluconate, potassium or sodium phosphate and magnesium sulfate.